JPRN-UMIN000011688已完成3 期
A phase III trial of S-1 vs. observation in patients with resected biliary tract cancer ASCOT : Adjuvant S-1 for CholangiOcarcinoma Trial (JCOG1202, ASCOT) - A phase III trial of S-1 vs. observation in patients with resected biliary tract cancer ASCOT : Adjuvant S-1 for CholangiOcarcinoma Trial (JCOG1202, ASCOT)
Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 350 人开始时间: 2013年9月9日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancy except carcinoma in situ or intramucosal tumor curatively treated with local therapy 2) Active infection requiring systemic therapy 3) Impossible to use both iodine and gadolinium due to being allergic to contrast agent 4) Fever of 38 degrees Celsius or over 5) Pregnant or lactating women or women of childbearing potential, male expecting partner's pregnancy 6) Severe psychiatric disease 7) Poorly controlled diabetes mellitus 8) Poorly controlled hypertension 9) Unstable angina pectoris within 3 weeks or with a history of myocardial infarction within 6 months 10) Patients requiring flucytosine, phenytoin or warfarin 11) Interstitial pneumonia, pulmonary fibrosis or severe emphysema
研究者
相似试验
未知
Unknown
A randomized phase III trial of S-1 versus S-1 plus irinotecan in advanced gastric cancer.Advanced gastric cancerJPRN-jRCT1080220081Yakult Honsha Co., Ltd. ,DAIICHI SANKYO Co.,Ltd.
已完成
3 期
Randomized phase III trial comparing adjuvant S-1 to capecitabine in stage III colorectal cancer (JCOG0910, CRC Adj-CAPS)Stage III colorectal cancerJPRN-UMIN000003272Japan Clinical Oncology Group(JCOG)1,550
招募中
1 期
MK-4280 and Pembrolizumab in Hematologic MalignanciesCTIS2023-503587-17-00Merck Sharp & Dohme LLC140
进行中（未招募）
1 期
MK-4280 and Pembrolizumab in Hematologic MalignanciesHematologic malignanciesMedDRA version: 21.1Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 100000004864EUCTR2018-001461-16-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.84
进行中（未招募）
1 期
MK-4280 and Pembrolizumab in Hematologic MalignanciesHematologic malignanciesMedDRA version: 21.1Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 100000004864EUCTR2018-001461-16-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.84